Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 7/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30808504 | 0.85 | ESR1 (0.36) | ESR1PLAAKDRCHEK1KDM4E | |
| SCHEMBL8464633 | 0.85 | MAPK9 (0.41) | ESR1KDRALDH1A1MAPTDYRK1A | |
| SCHEMBL27744512 | 0.83 | TNKS (0.39) | KDRKDM4EALDH1A1MAPTBRD4 | |
| SCHEMBL27890716 | 0.81 | MEN1 (0.39) | KDM4EALDH1A1MAPK14KMT2A | |
| SCHEMBL27890672 | 0.81 | IDO1 (0.41) | ESR1KDM4EALDH1A1MAPTACVR1 | |
| SCHEMBL27890677 | 0.81 | ALDH1A1 (0.42) | KDM4EALDH1A1MAPTMAP4K4BRD4 | |
| SCHEMBL2866599 | 0.81 | GAA (0.51) | ESR1PLAAKDRCHEK1KDM4E | |
| SCHEMBL14921747 | 0.81 | ESR1 (0.42) | ESR1PLAAKDRCHEK1KDM4E | |
| SCHEMBL10782643 | 0.78 | ESR1 (0.41) | ESR1KDRCHEK1KDM4EALDH1A1 | |
| SCHEMBL10782654 | 0.78 | ESR1 (0.41) | ESR1KDRCHEK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396505-A | Methods of treating inflammation | 维鲁公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-115379835-A | Methods of treating coronavirus | 维鲁公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4061349-A1 | METHODS OF TREATING CORONAVIRUS | Veru Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-112512522-A | Compounds for the treatment of triple negative breast and ovarian cancer | 田纳西大学研究基金会 | 2021-03-16 | — | — | CN | disclosed |
| CN-112437664-A | Compounds for the treatment of pancreatic cancer | 田纳西大学研究基金会 | 2021-03-02 | — | — | CN | disclosed |
| EP-2608671-B1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20180325872-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-11-15 | — | — | US | disclosed |
| US-10022356-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2014138279-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-09-12 | — | — | WO | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| CN-102690264-B | 2-phenyl-3-substituted-imidazo[1,2-a]pyridine derivatives and preparation method thereof | UNIVTAISHAN MEDICAL | 2014-07-02 | — | — | CN | disclosed |
| CN-103442566-A | Compounds for treatment of cancer | GTX INC | 2013-12-11 | — | — | CN | disclosed |
| WO-2012027481-A9 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2608671-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| CN-102883607-A | Compounds for the treatment of cancer | GTX INC (US) | 2013-01-16 | — | — | CN | disclosed |
| CN-102690264-A | 2-phenyl-3-substituted-imidazo[1,2-a]pyridine derivatives and preparation method thereof | UNIVTAISHAN MEDICAL | 2012-09-26 | — | — | CN | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180325872-A1 | COMPOUNDS FOR TREATMENT OF CANCER | BRAF, NRAS, RAF1 | ESR1 3985/4885PLAA 4514/4885KDR 1047/4885 |
| US-10022356-B2 | Compounds for treatment of cancer | BRAF, NRAS, RAF1 | ESR1 3985/4885PLAA 4514/4885KDR 1047/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ESR1 1342/4885PLAA 2916/4885KDR 2787/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | ESR1 1342/4885PLAA 2916/4885KDR 2787/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ESR1 1342/4885PLAA 2916/4885KDR 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.